Cryopyrin-Associated Periodic Syndromes - CAPS
Cryopyrin-associated periodic syndromes (CAPS) are a group of rare inherited autoinflammatory diseases. They are caused by mutations in the NLRP3 gene that lead to overproduction of interleukin-1 beta (IL-1β), one of the body's most potent inflammatory proteins.
The specialists at Haute-Derma focus on early diagnosis by combining careful clinical assessment with molecular genetic testing. Our goal is a precise, long-term management plan that frees patients from recurring bouts of fever and rash.
How CAPS Is Diagnosed at Haute-Derma
At Haute-Derma, diagnosing CAPS is a detailed process that combines careful clinical observation with the most advanced genetic testing available, so that rare variants are not missed:
- Rash pattern analysis: We look for hive-like papules that, unlike ordinary hives, itch little or not at all and often sting or burn instead.
- Temperature challenge testing: A controlled cold-exposure test lets us observe whether symptoms flare, which is particularly useful for identifying FCAS.
- Dermoscopy: To assess dilation of small vessels in the upper dermis and white blood cell infiltration around the vessels, without leakage of red blood cells.
- Molecular genetic testing: This is the key step for detecting NLRP3 mutations. We use next-generation sequencing (NGS) to pinpoint point mutations, including those present only in some cells (mosaicism).
- Multi-organ assessment: Audiometry to check for sensorineural hearing loss, an eye exam to screen for uveitis and papilledema, and serum amyloid A testing to gauge the risk of kidney complications.
- Differential diagnosis: Ruling out ordinary cold urticaria, Schnitzler syndrome and other systemic autoimmune diseases such as lupus erythematosus.
Clinical Types of CAPS
CAPS includes three forms of increasing severity, all driven by the same genetic mechanism:
- Familial cold autoinflammatory syndrome (FCAS): The mildest form, with episodes of hive-like rash, fever and joint pain after exposure to cold.
- Muckle-Wells syndrome (MWS): The intermediate form. Besides rash and fever, patients often develop progressive hearing loss and have a high risk of kidney disease from amyloid deposits.
- Neonatal-onset multisystem inflammatory disease (NOMID/CINCA): The most severe form, starting at birth, with chronic meningitis, serious bone and joint deformities and damage to the central nervous system.
Specialized Treatment of CAPS at Haute-Derma
Our treatment targets the root mechanism of the disease and focuses entirely on blocking the interleukin-1 (IL-1) inflammatory pathway:
- Modern IL-1 inhibitors: Biologics such as canakinumab or anakinra are the gold-standard agents. They neutralize IL-1β or block the IL-1 receptor, shutting down systemic inflammation within a short time.
- Dosing tailored to biological response: At Haute-Derma, we do not use a one-size-fits-all dose. Your doctor adjusts it based on inflammatory markers (such as CRP and SAA) and clinical signs to get the best results with the lowest cost and fewest side effects.
- Managing irreversible complications: For patients who already have hearing loss or bone and joint damage, we work with ENT and orthopedic specialists to provide supportive care and stop further progression.
- "Zero-flare" monitoring: Our aim is to bring patients to a state with no flares at all. Regular follow-up picks up early signs of smoldering inflammation even before anything shows on the skin.
- Genetic counseling and prevention: We help families understand how the disease is inherited and, where appropriate, offer prenatal screening options to protect the health of future generations.
